How TechStart SaaS Increased Trial Signups by 140%
TechStart, a B2B project management SaaS company, struggled with a 78% abandonment rate on their trial signup form. After migrating to NeuForms and implementing conversion optimization best practices, they achieved a 140% increase in trial starts and 45% improvement in activation rates. This case study details their transformation.
Short answer
TechStart, a B2B project management SaaS company, struggled with a 78% abandonment rate on their trial signup form. After migrating to NeuForms and implementing conversion optimization best practices, they achieved a 140% increase in trial starts and 45% improvement in activation rates. This case study details their transformation.
The Challenge
TechStart's original signup process used a legacy form builder with 12 required fields including company size, job title, phone number, and project details. Analytics revealed users dropped off at the phone number field (field 7) and 65% never reached the submit button. Mobile completion rates were particularly poor at just 8%. The lengthy form was creating friction that cost them an estimated 500 qualified trials monthly.
The Solution
Field Reduction: Consolidated to 4 fields (name, email, password, company) using progressive profiling to collect additional data during onboarding. Progressive Disclosure: Used conditional logic to show advanced fields only to enterprise prospects identified by email domain. Mobile Optimization: Implemented a single-column mobile design with larger touch targets and inline validation. Social Proof: Added 'Join 50,000+ teams' messaging and testimonial quotes to build trust. Exit-Intent Recovery: Implemented save-and-resume for users who abandoned mid-completion.
Results & Impact
Trial signups increased from 340/month to 816/month (+140%). Form completion rate improved from 22% to 68%. Mobile completion rate rose from 8% to 41%. Cost per trial decreased by 62% due to higher conversion. Sales team reported higher lead quality due to better qualification. Time-to-value improved as activation rates increased 45%.